Citations

Clear

17 citation(s) found for "Martinez, Felipe".

Health system patterns of imaging and fluid biomarker testing in the era of anti‐amyloid therapies
Robb, W Hudson , Kaur, Gurkiran , Huang, Steven K. , Martínez, Felipe Derteano, Nguyen, Ba Thang, Shin, Clifford , Conyers, Christopher T. , Grilli, Christopher, Upjohn, David P., Ortega, V E, Hohman, Timothy J., Keegan, Richard, Cogswell, Petrice M., Graff‐Radford, Jonathan, Johnson, Derek R., Ramanan, Vijay K., Koran, Mary Ellen, Huang, Steven, Nguyen, Ba, Shin, Clifford H, Grilli, Christopher B, Koran, Mary Ellen , Martinez, Felipe, Nguyen, Ba, Yang, Ming , Hohman, Timothy J. , Parent, Ephraim E. , Cogswell, Petrice M. , Graff‐Radford, Jonathan , Ramanan, Vijay K. , Koran, Mary Ellen I.

Mayo Clinic

Alzheimer's & Dementia | April 8, 2026 | Volume: 22 | Issue: 4 | Pages: No page available

10.1002/alz.71343 | PMID 41950049 Get It

Abstract INTRODUCTION Anti—amyloid‐β (Aβ) therapies are reshaping Alzheimer's disease (AD) management. Understanding changes in real‐world patterns of diagnostic testing and infusion chair usage is essential for optimizing access to care. METHODS Retrospective analysis of Mayo Clinic enterprise electronic health records (Jan 2019–Mar 2025) assessed trends in AD‐relevant brain imaging, fluid biomarkers, apolipoprotein E (APOE) testing, and lecanemab infusions. Rates of amyloid‐beta (Aβ) positivity by sex and age, APOE genotype frequencies, and lecanemab treatment initiation and discontinuation were evaluated. RESULTS Following national insurance coverage changes, lecanemab infusions grew by 110 infusions per quarter to 605 in Q1 2025. Aβ positron emission tomography scans increased (+22/quarter), cerebrospinal fluid biomarker orders declined (−25/quarter), and plasma p‐tau 217 orders rapidly increased (+238/quarter). Females were more likely to be Aβ positive ( p < 0.006). APOE ‐ε4 homozygotes were less likely to initiate lecanemab (HR = 0.11, p < 0.001). DISCUSSION The adoption of anti‐Aβ therapies coincided with a rapid shift in diagnostic workflows.
Practical Interpretation of Bone Scintigraphy: Metastases, Fractures, and Beyond
Haug, Logan P. , Brown, Parker J. , Bishay, Steven , Lombardi, Alecio F. , Huang, Steve S. , Shin, Clifford , Koran, Mary Ellen I. , Long, J. B., Martínez, Felipe Derteano, Nguyen, Ba D. , Long, Jeremiah R. , Bishay, Steven E , Long, Jeremiah , Martinez, Felipe , Nguyen, B D , Koran, Mary Ellen

Mayo Clinic

RadioGraphics | January 15, 2026 | Volume: 46 | Issue: 2 | Pages: No page available

10.1148/rg.250055 | PMID 41538361 Get It

Bone scintigraphy is a valuable adjunct to cross-sectional imaging and can be used to evaluate disease extent in multifocal processes such as blastic osseous metastatic disease, provide diagnostic information to aid in problem solving in challenging cases, and serve as the primary diagnostic modality for diseases that manifest with pathognomonic scintigraphic appearances.
Glomus Tumor of the Finger Diagnosed on Bone Scintigraphy
Lombardi, Alecio F. , Martinez, Felipe , Long, Jeremiah R.

Mayo Clinic

World Journal of Nuclear Medicine | February 20, 2025 | Volume: 24 | Issue: 02 | Pages: 181-184

10.1055/s-0045-1802955 | PMID 40336861 Get It

AbstractA 60-year-old woman with chronic pain in the left long finger, occasionally involving the ring finger and intermittently extending to the hand, wrist, and distal forearm, was referred for radiographs and a triple-phase technetium-99m methylene diphosphonate bone scintigraphy to evaluate for possible complex regional pain syndrome. Initial radiographs were normal. A three-phase bone scan revealed focal radiotracer uptake at the distal aspect of the long finger during the blood pool phase only, with normal blood flow and delayed phases, suggesting a hypervascular soft tissue tumor. Follow-up magnetic resonance imaging showed a hypervascular nodule in the nail bed of the long finger. The lesion was surgically resected, and pathology results confirmed the diagnosis of a glomus tumor.
Teflon Granuloma With Active Inflammation: A Cause of Recurrent Trigeminal Neuralgia After Microvascular Decompression
Herber, Steven C., Zimmerman, Richard S. , Yang, Ming , Martinez, Felipe , Herber, Steven, Chen, Alicia

Mayo Clinic

Clinical Nuclear Medicine | October 31, 2024 | Volume: 49 | Issue: 12 | Pages: 1105-1108

10.1097/rlu.0000000000005444 | PMID 39479994 Get It

Abstract Trigeminal neuralgia (TN) is characterized by excruciating facial pain usually caused by neurovascular compression of the trigeminal nerve roots. TN can be treated medically or invasively. Microvascular decompression is the procedure of choice and usually results in complete symptom relief. During surgical decompression, Teflon can be placed between the offending vessel and the nerve root entry zone. In some cases, chronic Teflon-related inflammation can cause recurrent TN, which might lead to additional surgical intervention. We present imaging and histopathological correlation of a patient presenting with intractable recurrent TN approximately 2 years after microvascular decompression with Teflon implant.
Outcomes and effects of sacubitril/valsartan according to NT-proBNP level in patients with heart failure: a patient-level pooled analysis of the PARADIGM-HF and PARAGON-HF trials
Martinez, Felipe A, REDFIELD, M, Rouleau, Jean‐Lucien, Veldhuisen, D.J. van, Zannad, Faı̈ez , Packer, Milton, Solomon, Scott D. , Kondo, Toru , Jhund, Pardeep S. , Anand, Inder S. , Desai, Akshay S , Lam, Carolyn S.P. , Maggioni, Aldo P. , Martínez, Felipe A. , Redfield, Margaret M. , Zile, Michael R. , Packer, Milton , Solomon, Scott David , McMurray, John J.V.

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.1099 Get It

Abstract Background NT-proBNP levels are associated with disease severity and outcomes in patients with HF across the spectrum of LVEF. Recently, it has been suggested that the effectiveness of certain treatments may vary by NT-proBNP level with greater benefit from omecamtiv mecarbil, and smaller benefit from vericiguat, in patients with higher NT-proBNP levels. We examined the benefit of sacubitril/valsartan on outcomes across the range of NT-proBNP levels in patients with HFrEF/HFmrEF/HFpEF. Purpose To evaluate clinical outcomes, and the efficacy of sacubitril/valsartan, according to NT-proBNP levels, in patients with HFrEF/HFmrEF/HFpEF, using the pooled dataset of participants in the PARADIGM-HF and PARAGON-HF trials. Methods The PARADIGM-HF (n=8399) and PARAGON-HF (n=4822) trials enrolled patients with HF, functional limitation, and elevated NT-proBNP levels. Patients with LVEF ≤40% were randomized to sacubitril/valsartan 200 mg twice daily or enalapril 10mg twice daily in PARADIGM-HF, and those with LVEF ≥45% to sacubitril/valsartan 200 mg twice daily or valsartan 160mg twice daily in PARAGON-HF. Patients were categorized by quintiles of NT-proBNP level and using NT-proBNP as a continuous variable, analysed using restricted cubic splines. The primary outcome in the present study was the composite of cardiovascular death or HF hospitalization. Results Among the 13195 patients in the pooled PARADIGM-HF and PARAGON-HF dataset, 13142 (99.6%) patients with baseline NT-proBNP were analysed. Patients with higher NT-proBNP levels were more often male, had lower body mass index and LVEF, worse New York Heart Association functional class, worse kidney function, and more atrial fibrillation, while age was similar across NT-proBNP levels. The rate of the primary outcome (per 100 person-years) increased with NT-proBNP level: quintile 1, 5.9 (95%CI 5.3-6.5); quintile 2, 7.5 (95%CI 6.9-8.2); quintile 3, 9.0 (95%CI 8.2-9.7); quintile 4, 12.0 (95%CI 11.1-12.9); and quintile 5, 20.8 (95%CI 19.6-22.2) (Figure 1). Similar trends were observed for other outcomes. The benefit of sacubitril/valsartan was consistent across NT-proBNP levels: the hazard ratio for the primary outcome in NT-proBNP quintile 1 was 0.79 (95%CI 0.65-0.96); quintile 2, 0.87 (95%CI 0.72-1.04); quintile 3, 0.79 (95%CI 0.66-0.93); quintile 4, 0.85 (95%CI 0.73-0.99); and quintile 5, 0.86 (95%CI 0.76-0.97), P-interaction=0.86. The consistent benefit of sacubitril/valsartan was also seen when NT-proBNP was analysed as a continuous variable (Figure 2). The absolute benefit was greatest in quintile 5 of NT-proBNP; the number needed to treat for quintile 5 was 16 versus 37 for the quintile 1 for the primary endpoint. Conclusions Patients with higher NT-proBNP had worse outcomes, but the benefits of sacubitril valsartan were consistent across the range of NT-proBNP levels of participants in PARADIGM-HF and PARAGON-HF.Kaplan-Meier curvesEffect of sac/val across NT-proBNP range
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction
Henderson, A D, Lam, C S P, Martinez, Felipe A, Packer, Milton, Redfield, Margaret M. , Rouleau, Jean‐Lucien, Veldhuisen, D.J. van, Vaduganathan, M, Zannad, Faı̈ez , Jhund, P S, Solomon, Scott D. , Matsumoto, Shingo , Boer, Rudolf A. de , Lam, C S P, Martínez, Felipe A. , Packer, Milton , Zile, Michael R. , Jhund, Pardeep S. , Solomon, Scott David , McMurray, John J.V.

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.1067 Get It

Abstract Background Concerns have been raised about the appropriateness of use and safety of beta-blockers (BBs) in patients with heart failure and mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF). However, randomized trial evidence is still lacking. Purpose To perform an observational analysis of the association between BB use and clinical outcomes in a large dataset of patients with HFmrEF and HFpEF. Methods We pooled individual patient data from four large HFmrEF/HFpEF trials (I-Preserve, TOPCAT, PARAGON-HF, and DELIVER). The associations between baseline BB use and outcomes were analyzed. The primary outcome was the composite of cardiovascular death or HF hospitalization. Results Among the 16,951 patients included, the mean left ventricular ejection fraction (LVEF) was 56.8%, and 13,400 (79.1%) had HFpEF (LVEF ≥50%). Overall, 12,812 patients (75.6%) received a BB. The median bisoprolol-equivalent dose of BB was 5.0 (Q1-Q3: 2.5-5.0) mg with BB continuation rates of 95.1% at 1 year and 93.1% at 2 years (in patients who survived more than 1 and 2 years, respectively). Overall, the hazard ratio (HR) for the primary outcome did not differ between BB users and non-users (HR: 0.98 [95% CI: 0.91-1.05]) but among patients with HFmrEF, BB users had a lower HR (0.84 [95% CI 0.71-0.98]), whereas in HFpEF the HR was similar BB users and non-users (0.99 [95% CI 0.92-1.08]). However, after comprehensive adjustment for known prognostic variables, including NT-proBNP, BB use was associated with a better outcome in the overall cohort (HR 0.81 [0.74-0.88]), and this association was maintained across the range of LVEF (Figure 1). In subgroup analyses, the risk of the primary outcome was similar in BB users and non-users with or without a history of myocardial infarction, with or without a history of hypertension, or with or without a baseline heart rate &lt;70 bpm. By contrast, a better outcome with BB use was seen in patients with atrial fibrillation compared to those without atrial fibrillation (Figure 2). Conclusions Although this is an observational analysis of non-randomized treatment, there was no suggestion that BB use was associated with worse HF outcomes even after extensive adjustment for other prognostic variables. Figure Legends Figure 1. Association between beta-blocker use and outcomes across the range of LVEF. Risk in beta-blocker users versus non-users is shown as an adjusted continuous hazard ratio Figure 2. Association between beta-blocker use and non-use in the overall population and clinically relevant patient subgroups, shown as an adjusted hazard ratio (HR). The outcome analyzed was the composite of CV death or HF hospitalization (primary outcome)Figure 1Figure 2
Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF
Shen, Li , Dewan, Pooja , Cunningham, Jonathan W. , Jhund, Pardeep S. , Chandra, Alvin , Chiang, Lu‐May, Claggett, Brian , Desai, Akshay S. , Gong, Jianjian , Lefkowitz, Marty , Maggioni, Aldo P. , Martínez, Felipe A. , Redfield, Margaret M. , Rouleau, Jean L. , Veldhuisen, Dirk J. van , Zannad, Faı̈ez , Solomon, Scott D. , Ferreira, João Pedro , Cunningham, Jonathan W , Jhund, Pardeep S , Chandra, Alvin , Claggett, Brian L , Desai, Akshay S , Lam, Carolyn S P , Lefkowitz, Martin P , Maggioni, Aldo P , Martinez, Felipe , Packer, Milton , Redfield, Margaret M , Rouleau, Jean L , Van Veldhuisen, Dirk J , Zannad, Faiez , Zile, Michael R , Solomon, Scott David , Ferreira, João Pedro , Anand, Inder S. , Lam, Carolyn S.P. , Packer, Milton , Zile, Michael R. , McMurray, John J.V.

Mayo Clinic

Circulation | October 21, 2024 | Volume: 150 | Issue: 24 | Pages: 1913-1927

10.1161/circulationaha.124.070553 | PMID 39429145 Get It

BACKGROUND: Cognitive impairment is common in patients with heart failure and preserved ejection fraction but its clinical correlates and prognostic associations are poorly understood. METHODS: We analyzed cognitive function, using the Mini-Mental State Examination (MMSE), in patients with heart failure and preserved ejection fraction enrolled in a prespecified substudy of the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in Heart Failure With Preserved Ejection Fraction). Logistic regression analyses were performed to determine the variables associated with lower MMSE scores at baseline and postbaseline decline in MMSE scores at 48 weeks. Cox proportional hazards regression and semiparametric proportional rates models were used to examine the risk of clinical outcomes related to baseline MMSE scores, and decline in MMSE scores during follow-up, adjusted for prognostic variables including NT-proBNP (N-terminal pro-B-type natriuretic peptide). RESULTS: At baseline, cognitive function was normal (MMSE score 28–30) in 1809 of 2895 patients (62.5%), borderline (score 24–27) in 794 (27.4%), and impaired (score <24) in 292 (10.1%). Variables associated with both a lower MMSE score at baseline and a decline in score from baseline included older age, a history of stroke or transient ischemic attack, and lower serum albumin. Compared with those with baseline MMSE scores of 28 to 30, patients in the lower MMSE score categories had a stepwise increase in the risk of the composite of time to first heart failure hospitalization or cardiovascular death, with an adjusted hazard ratio of 1.27 (95% CI, 1.06–1.53) for those with scores of 24 to 27 and 1.58 (95% CI, 1.21–2.06) for those with scores <24, respectively. These associations were also found for the individual components of the composite and all-cause death. Likewise, cognitive impairment was associated with a 50% higher risk of total (first and repeat) heart failure hospitalizations and cardiovascular deaths. Examining the change in MMSE score from baseline, a decrease in MMSE score during follow-up was associated with a higher risk of death. CONCLUSIONS: In patients with heart failure and preserved ejection fraction, even modest baseline impairment of cognitive function was associated with worse outcomes, including death. A decline in MMSE score during follow-up was a strong predictor of mortality, independent of other prognostic variables.
Beta-Blocker Use and Outcomes in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fraction
Henderson, Alasdair D , Shen, Li , Campbell, Ross T. , Boer, Rudolf A. de , Lam, Carolyn S.P., Maggioni, Aldo P. , Martínez, Felipe A. , Redfield, Margaret M. , Rouleau, Jean L. , Veldhuisen, Dirk Jan van, Zannad, Faı̈ez , Solomon, Scott, de Boer, Rudolf A , Maggioni, Aldo P , Matsumoto, Shingo , Kondo, Toru , Yang, Mingming , Anand, Inder S. , Desai, Akshay S , Lam, Carolyn S.P. , Packer, Milton , Veldhuisen, Dirk J. van , Vaduganathan, Muthiah , Zile, Michael R. , Jhund, Pardeep S. , McMurray, John J.V.

Mayo Clinic

European Journal of Heart Failure | August 31, 2024 | Volume: 27 | Issue: 1 | Pages: 124-139

10.1002/ejhf.3383 | PMID 39215677 Get It

ABSTRACT Aims In the absence of randomized trial evidence, we performed a large observational analysis of the association between beta-blocker (BB) use and clinical outcomes in patients with heart failure (HF) and mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF). Methods and results We pooled individual patient data from four large HFmrEF/HFpEF trials (I-Preserve, TOPCAT, PARAGON-HF, and DELIVER). The primary outcome was the composite of cardiovascular death or HF hospitalization. Among the 16 951 patients included, the mean left ventricular ejection fraction (LVEF) was 56.8%, and 13 400 (79.1%) had HFpEF (LVEF ≥50%). Overall, 12 812 patients (75.6%) received a BB. The median bisoprolol-equivalent dose of BB was 5.0 (Q1–Q3: 2.5–5.0) mg with BB continuation rates of 93.1% at 2 years (in survivors). The unadjusted hazard ratio (HR) for the primary outcome did not differ between BB users and non-users (HR 0.98, 95% confidence interval [CI] 0.91–1.05), but the adjusted HR was lower in BB users than non-users (0.81, 95% CI 0.74–0.88), and this association was maintained across LVEF (pinteraction = 0.88). In subgroup analyses, the adjusted risk of the primary outcome was similar in BB users and non-users with or without a history of myocardial infarction, hypertension, or a baseline heart rate &lt;70 bpm. By contrast, a better outcome with BB use was seen in patients with atrial fibrillation compared to those without atrial fibrillation (pintreraction = 0.02). Conclusions In this observational analysis of non-randomized BB treatment, there was no suggestion that BB use was associated with worse HF outcomes in HFmrEF/HFpEF, even after extensive adjustment for other prognostic variables.
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF
Dewan, Pooja , Shen, Li , Jhund, Pardeep S. , Chandra, Alvin , Chiang, Lu‐May, Claggett, Brian , Desai, Akshay S. , Gong, Jianjian , Lefkowitz, Marty , Maggioni, Aldo P. , Martínez, Felipe A. , Redfield, Margaret M. , Rouleau, Jean L. , Veldhuisen, Dirk J. van , Zannad, Faı̈ez , Solomon, Scott D. , Jhund, Pardeep S , Chandra, Alvin , Claggett, Brian L , Desai, Akshay S , Lam, Carolyn S P , Lefkowitz, Martin P , Maggioni, Aldo P , Martinez, Felipe , Packer, Milton , Redfield, Margaret M , Rouleau, Jean L , Van Veldhuisen, Dirk J , Zannad, Faiez , Zile, Michael R , Solomon, Scott David , Ferreira, João Pedro , Anand, Inder S. , Lam, Carolyn S.P. , Packer, Milton , Zile, Michael R. , McMurray, John J.V.

Mayo Clinic

Circulation | June 6, 2024 | Volume: 150 | Issue: 4 | Pages: 272-282

10.1161/circulationaha.124.068774 | PMID 38841854 Get It

BACKGROUND: A hypothetical concern has been raised that sacubitril/valsartan might cause cognitive impairment because neprilysin is one of several enzymes degrading amyloid-β peptides in the brain, some of which are neurotoxic and linked to Alzheimer-type dementia. To address this, we examined the effect of sacubitril/valsartan compared with valsartan on cognitive function in patients with heart failure with preserved ejection fraction in a prespecified substudy of PARAGON-HF (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in Heart Failure With Preserved Ejection Fraction). METHODS: In PARAGON-HF, serial assessment of cognitive function was conducted in a subset of patients with the Mini-Mental State Examination (MMSE; score range, 0–30, with lower scores reflecting worse cognitive function). The prespecified primary analysis of this substudy was the change from baseline in MMSE score at 96 weeks. Other post hoc analyses included cognitive decline (fall in MMSE score of ≥3 points), cognitive impairment (MMSE score <24), or the occurrence of dementia-related adverse events. RESULTS: Among 2895 patients included in the MMSE substudy with baseline MMSE score measured, 1453 patients were assigned to sacubitril/valsartan and 1442 to valsartan. Their mean age was 73 years, and the median follow-up was 32 months. The mean±SD MMSE score at randomization was 27.4±3.0 in the sacubitril/valsartan group, with 10% having an MMSE score <24; the corresponding numbers were nearly identical in the valsartan group. The mean change from baseline to 96 weeks in the sacubitril/valsartan group was −0.05 (SE, 0.07); the corresponding change in the valsartan group was −0.04 (0.07). The mean between-treatment difference at week 96 was −0.01 (95% CI, −0.20 to 0.19; P =0.95). Analyses of a ≥3-point decline in MMSE, decrease to a score <24, dementia-related adverse events, and combinations of these showed no difference between sacubitril/valsartan and valsartan. No difference was found in the subgroup of patients tested for apolipoprotein E ε4 allele genotype. CONCLUSIONS: Patients with heart failure with preserved ejection fraction in PARAGON-HF had relatively low baseline MMSE scores. Cognitive change, measured by MMSE, did not differ between treatment with sacubitril/valsartan and treatment with valsartan in patients with heart failure with preserved ejection fraction. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01920711.
Multi-Modality Imaging in Vasculitis
Allam, Mohamed , Ali, Nima Baba , Mahmoud, Ahmed , Scalia, Isabel G. , Farina, Juan M. , Abbas, Mohammed Tiseer , Pereyra, Milagros , Kamel, Moaz, Awad, Kamal A., Wang, Yuxiang , Barry, Timothy , Huang, Steve S. , Yang, Ming , Jokerst, Clinton, Martinez, Felipe , Arsanjani, Reza , Awad, Kamal , Allam, Mohamed N , Baba Ali, Nima, Mahmoud, Ahmed K , Kamel, Moaz A, Nguyen, Ba D. , Martinez, Felipe , Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Scalia, Isabel G , Abbas, Mohammed Tiseer , Awad, Kamal

Mayo Clinic

Diagnostics | April 18, 2024 | Volume: 14 | Issue: 8 | Pages: 838

10.3390/diagnostics14080838 | PMID 38667483 Get It

Systemic vasculitides are a rare and complex group of diseases that can affect multiple organ systems. Clinically, presentation may be vague and non-specific and as such, diagnosis and subsequent management are challenging. These entities are typically classified by the size of vessel involved, including large-vessel vasculitis (giant cell arteritis, Takayasu’s arteritis, and clinically isolated aortitis), medium-vessel vasculitis (including polyarteritis nodosa and Kawasaki disease), and small-vessel vasculitis (granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis). There are also other systemic vasculitides that do not fit in to these categories, such as Behcet’s disease, Cogan syndrome, and IgG4-related disease. Advances in medical imaging modalities have revolutionized the approach to diagnosis of these diseases. Specifically, color Doppler ultrasound, computed tomography and angiography, magnetic resonance imaging, positron emission tomography, or invasive catheterization as indicated have become fundamental in the work up of any patient with suspected systemic or localized vasculitis. This review presents the key diagnostic imaging modalities and their clinical utility in the evaluation of systemic vasculitis.